Research
Hormonal
Circadian misalignment (desynchrony between sleep/eating times and internal clocks) independently reduces insulin sensitivity and exacerbates the negative metabolic effects of sleep restriction.
Align your sleep and meal times with your natural circadian rhythm. Circadian misalignment (e.g., eating late, sleeping at odd hours) reduces insulin sensitivity and worsens glucose metabolism. For shift workers, strategies to align internal clocks with external schedules are critical to mitigate diabetes risk.
GoodSupportsHIGH confidence
When the circadian system is misaligned, desynchrony between the central and peripheral clocks occurs and glucose metabolism is adversely affected.
Why this rating
Based on forced desynchrony protocols in laboratory settings.
Source
Impact of Sleep and Circadian Disruption on Energy Balance and Diabetes: A Summary of Workshop Discussions
Deanna M. Arble et al. · SLEEP · 2015
DOI 10.5665/sleep.5226
narrative_reviewCited 180×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic sleep restriction (4-5 hours/night) significantly reduces insulin sensitivity and increases diabetes risk in healthy adults.Good
- Continuous Positive Airway Pressure (CPAP) treatment for Obstructive Sleep Apnea (OSA) improves insulin resistance in patients without diabetes.Moderate
- Time-Restricted Feeding (TRF) aligned with the active period improves metabolic health markers (body weight, cholesterol, insulin levels) in mice without reducing overall food intake.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →